{"id":2504,"date":"2023-09-25T17:23:07","date_gmt":"2023-09-25T15:23:07","guid":{"rendered":"https:\/\/oncngs.eu\/?p=2504"},"modified":"2023-09-26T09:42:30","modified_gmt":"2023-09-26T07:42:30","slug":"oncngs-pre-commercial-procurement-has-entered-in-prototyping-phase-phase-2-with-the-selection-of-three-innovative-approaches-for-future-next-generation-sequencing-ngs-tests-for","status":"publish","type":"post","link":"https:\/\/oncngs.eu\/index.php\/2023\/09\/25\/oncngs-pre-commercial-procurement-has-entered-in-prototyping-phase-phase-2-with-the-selection-of-three-innovative-approaches-for-future-next-generation-sequencing-ngs-tests-for\/","title":{"rendered":"OncNGS has entered in prototyping phase (Phase 2) with the selection of\u00a0three\u00a0innovative\u00a0approaches for future Next-Generation Sequencing (NGS) tests for cancer"},"content":{"rendered":"\n<p>The Call-off for Phase 2 was launched in early July 2023 where four successful suppliers from Phase 1 were invited to submit an offer. &nbsp;<\/p>\n\n\n\n<p>OncNGS procurers\u2019 team, representing healthcare providers from Belgium, France, Germany, Italy and Spain, selected three suppliers to proceed to a phase of prototype development after a thorough evaluation process.<\/p>\n\n\n\n<p>The&nbsp;contracts were awarded to:<\/p>\n\n\n\n<p>\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>AGILENT TECHNOLOGIES BELGIUM<\/strong><\/p>\n\n\n\n<p>\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>KU LEUVEN<\/strong><\/p>\n\n\n\n<p>\u00b7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>HUFIAT CANCER LIQUIDATION<\/strong>&nbsp;&#8211; Consortium members: Euformatics Oy (lead tenderer), Oncompas Medicine, ViennaLab Diagnostics<\/p>\n\n\n\n<p>Since August 31 2023, awarded&nbsp;suppliers have been invited to start Phase 2&nbsp;and further research and develop working prototypes,&nbsp;over a period of twelve months.<\/p>\n\n\n\n<p>After the evaluation that will follow the end of this period, the&nbsp;successful contractors&nbsp;will be invited to submit an offer for&nbsp;Phase 3, in which the developed&nbsp;prototypes will move forward to clinical&nbsp;testing at the procurer\u2019s sites.<\/p>\n\n\n\n<p><strong>The call-off: moving from four&nbsp;designed solutions&nbsp;to three&nbsp;working&nbsp;prototypes<\/strong><\/p>\n\n\n\n<p>The oncNGS call-off is an evaluation process that is used in the PCP to select the best approaches and offer them a chance to continue into the next phase of research and development.<\/p>\n\n\n\n<p>Among the offers received during the initial&nbsp;oncNGS &nbsp;call for tender (2022), four innovative&nbsp;proposals were&nbsp;selected&nbsp;and&nbsp;awarded contracts for&nbsp;Phase 1 in&nbsp;January&nbsp;2023. In the past few months, these 4&nbsp;suppliers&nbsp;worked on demonstrating the technical, medical, financial and commercial feasibility of the proposed concepts and approaches to meet the procurement requirements. Following the Call-off for Phase 2, three approaches have been selected.<\/p>\n\n\n\n<p><strong>From the design to a functioning system<\/strong><\/p>\n\n\n\n<p>The design that suppliers envisioned in Phase 1 will now turn into a reality. A functioning system will be developed by the suppliers in collaboration with the procuring healthcare providers&nbsp;over the next 12&nbsp;months. The aim is to verify&nbsp;if&nbsp;the prototype\u2019s main features meet the functional requirements and the expected performance while ensuring the solution is user-centred.<\/p>\n","protected":false},"excerpt":{"rendered":"The Call-off for Phase 2 was launched in early July 2023 where four successful suppliers from Phase 1 were invited to submit an offer. &nbsp; OncNGS procurers\u2019 team, representing healthcare providers from Belgium, France, Germany, Italy and Spain, selected three suppliers to proceed to a phase of prototype development after a thorough evaluation process. The&nbsp;contracts[&#8230;]","protected":false},"author":2,"featured_media":2506,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[],"_links":{"self":[{"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/posts\/2504"}],"collection":[{"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/comments?post=2504"}],"version-history":[{"count":3,"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/posts\/2504\/revisions"}],"predecessor-version":[{"id":2508,"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/posts\/2504\/revisions\/2508"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/media\/2506"}],"wp:attachment":[{"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/media?parent=2504"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/categories?post=2504"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/tags?post=2504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}